EMA — authorised 17 August 2022
- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Status: approved
🇪🇺 Reyvow in European Union
EMA authorised Reyvow on 17 August 2022
Marketing authorisations
EMA — authorised 17 August 2022
- Application: EMEA/H/C/005332
- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Local brand name: Rayvow
- Indication: RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
- Status: approved
Reyvow in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in European Union
Frequently asked questions
Is Reyvow approved in European Union?
Yes. EMA authorised it on 17 August 2022; EMA authorised it on 17 August 2022.
Who is the marketing authorisation holder for Reyvow in European Union?
Eli Lilly Nederland B.V. holds the EU marketing authorisation.